| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/20/2001 | CA2402865A1 Opioid formulations |
| 09/20/2001 | CA2402846A1 Treatment of rosacea |
| 09/20/2001 | CA2402710A1 Use of a cephalotaxine and an antiproliferative agent in treating cellular proliferative disease |
| 09/20/2001 | CA2402645A1 Modulation of cardiovascular injury |
| 09/20/2001 | CA2402642A1 Method of chlamydia prophylaxis |
| 09/20/2001 | CA2402559A1 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
| 09/20/2001 | CA2402557A1 Method for the preparation of citalopram |
| 09/20/2001 | CA2402553A1 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans |
| 09/20/2001 | CA2402549A1 Substituted beta-carbolines |
| 09/20/2001 | CA2402427A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 09/20/2001 | CA2402413A1 Compositions and methods for affecting osteogenesis |
| 09/20/2001 | CA2402402A1 Use of (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treating adverse effects of anti-parkinsonian drugs |
| 09/20/2001 | CA2402388A1 Method for the preparation of citalopram |
| 09/20/2001 | CA2402386A1 Method for the preparation of citalopram |
| 09/20/2001 | CA2402312A1 Treatment of herpes infection using immunomodulatory polynucleotide sequences |
| 09/20/2001 | CA2402296A1 Intradermal-penetration agents for topical local anesthetic administration |
| 09/20/2001 | CA2402294A1 Immunomodulatory formulations and methods for use thereof |
| 09/20/2001 | CA2402276A1 Carbohydrate system and a method for providing nutriton to a diabetic |
| 09/20/2001 | CA2402259A1 Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections |
| 09/20/2001 | CA2402250A1 Immunomodulatory polynucleotide sequences for use in suppressing hepatitis virus infection |
| 09/20/2001 | CA2402122A1 D-enantiomer of dfmo and methods of use therefor |
| 09/20/2001 | CA2402120A1 The use of plant extracts and sugars to protect keratinous tissue |
| 09/20/2001 | CA2402041A1 Antisense oligonucleotides of the human chk1 gene and uses thereof |
| 09/20/2001 | CA2402025A1 Nystatin formulation having reduced toxicity |
| 09/20/2001 | CA2402014A1 Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections |
| 09/20/2001 | CA2401873A1 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| 09/20/2001 | CA2401273A1 Il-17 receptor like molecules and uses thereof |
| 09/20/2001 | CA2401267A1 Use of natural compounds having antiangiogenic activity |
| 09/20/2001 | CA2400370A1 Nucleoside compounds and uses thereof |
| 09/20/2001 | CA2400043A1 Antiviral prodrugs |
| 09/20/2001 | CA2373411A1 5-substituted arylpyrimidines |
| 09/20/2001 | CA2373237A1 Methods and compositions for treating and preventing posterior segment ophthalmic disorders |
| 09/19/2001 | EP1134229A2 Method of preparing clarithromycin of form II crystals |
| 09/19/2001 | EP1134222A1 IMIDAZO[4,5-b]PYRIDINIUMMETHYL-CONTAINING CEPHEM COMPOUNDS HAVING BROAD ANTIBACTERIAL SPECTRUM |
| 09/19/2001 | EP1134221A1 Substituted beta-carbolines as lkB kinase inhibitors |
| 09/19/2001 | EP1134220A1 Benzoxazole derivatives and drugs containing the same as the active ingredient |
| 09/19/2001 | EP1134219A1 Cycloalkyl-substituted aminomethylpyrrolidine derivatives |
| 09/19/2001 | EP1134216A1 Anti-drug resistant strain agents and antichlamydia agents |
| 09/19/2001 | EP1134215A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases |
| 09/19/2001 | EP1133997A2 Treatment of immune diseases with beta-interferon |
| 09/19/2001 | EP1133996A1 Medicinal compositions for periodic administration |
| 09/19/2001 | EP1133994A1 A method for reversing the immunosuppressive effects of the Melanoma Inhibitory Activity "MIA" |
| 09/19/2001 | EP1133993A1 Substances for the treatment of spinal muscular atrophy |
| 09/19/2001 | EP1133992A1 Novel pharmacological activities of curcuma longa extracts |
| 09/19/2001 | EP1133989A2 Polymer compositions for use in therapy |
| 09/19/2001 | EP1133988A1 Mixture comprising an inhibitor or suppressor of a gene and a molecule binding to an expression product of that gene |
| 09/19/2001 | EP1133987A1 Treatment of inflammatory dermatoses with combinations of erythromycin or clarythromycin, metronidazole and a hydrogen pump inhibitor |
| 09/19/2001 | EP1133986A1 Use of deramciclane for the treatment of anxiety and depression |
| 09/19/2001 | EP1133981A2 Use of light-screening combinations containing 4,4-Diarylbutadienes as photostable UV-filters in cosmetic and pharmaceutic preparations |
| 09/19/2001 | EP1133979A2 Use of specific fatty compounds for modifying the physico-chemical properties of the skin and/or the mucous membrane as agents for preventing or reducing the adhesion of micro-organisms thereon |
| 09/19/2001 | EP1133699A1 Prevention and treatment of amyloid-associated disorders |
| 09/19/2001 | EP1133692A1 Methods of identifying viral therapeutics |
| 09/19/2001 | EP1133575A2 Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2 |
| 09/19/2001 | EP1133561A2 Protein fragments for use in protein targeting |
| 09/19/2001 | EP1133558A1 Compositions and methods for increasing bone mineralization |
| 09/19/2001 | EP1133516A1 Chromosome 17p-linked prostate cancer susceptibility gene |
| 09/19/2001 | EP1133512A2 Benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133510A2 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133509A1 Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133508A2 Benzylglycosylamides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133507A2 Benzyllactobionamides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133506A2 Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133500A1 Organophosphorous compounds and the use thereof |
| 09/19/2001 | EP1133497A1 Crystal modification b of 8-cyano-1- cyclopropyl -7-(1s,6s-2, 8-diazabicyclo 4.3.0]nonan -8-yl)-6- fluoro-1,4- dihydro-4- oxo-3-quinoline carboxylic acid |
| 09/19/2001 | EP1133496A1 Crystal modification a of 8-cyano-1- cyclopropyl -7-(1s,6s-2, 8-diazabicyclo 4.3.0]nonan -8-yl)-6- fluoro-1, 4-dihydro- 4-oxo-3- quinoline carboxylic acid |
| 09/19/2001 | EP1133495A1 Semi-hydrochloride of 8-cyan-1- cyclopropyl -7-(1s,6s-2 ,8-diazabicyclo 4.3.0]nonan -8-yl)-6- fluoro-1, 4-dihydro -4-oxo-3- quinoline carboxylic acid |
| 09/19/2001 | EP1133494A1 8-azabicyclo 3.2.1]oct-2-ene and -octane derivatives |
| 09/19/2001 | EP1133493A1 Oxazolidinone antibacterial agents having a thiocarbonyl functionality |
| 09/19/2001 | EP1133492A1 Process for the preparation of paroxetine hydrochloride |
| 09/19/2001 | EP1133491A1 Novel benzofurane derivatives, preparation method, use as medicines and pharmaceutical compositions containing same |
| 09/19/2001 | EP1133489A1 Isonipecotamides for the treatment of integrin-mediated disorders |
| 09/19/2001 | EP1133488A1 Propanoic acid derivatives as integrin inhibitors |
| 09/19/2001 | EP1133487A1 Scavenger compounds |
| 09/19/2001 | EP1133486A2 Nonsteroidal antiinflammatories |
| 09/19/2001 | EP1133484A2 Heterocyclic derivatives and their use as integrin inhibitors |
| 09/19/2001 | EP1133483A1 Il-5 inhibiting 6-azauracil derivatives |
| 09/19/2001 | EP1133482A1 Il-5 inhibiting 6-azauracil derivatives |
| 09/19/2001 | EP1133481A1 Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors |
| 09/19/2001 | EP1133480A1 Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors |
| 09/19/2001 | EP1133479A1 Quinoline and quinoxaline compounds |
| 09/19/2001 | EP1133478A1 Novel acylguanidine derivatives, method for preparing same, application as medicines and pharmaceutical compositions containing them |
| 09/19/2001 | EP1133477A1 Substituted benzimidazoles and their use as parp inhibitors |
| 09/19/2001 | EP1133476A1 Iminoguanidine derivatives, preparation method, use as medicines |
| 09/19/2001 | EP1133475A1 Substituted benzo de]isoquinoline-1,3-diones |
| 09/19/2001 | EP1133474A1 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators |
| 09/19/2001 | EP1133473A1 New manufacturing process |
| 09/19/2001 | EP1133471A1 Hydrazine derivatives |
| 09/19/2001 | EP1133467A1 Ion channel modulating agents |
| 09/19/2001 | EP1133459A1 Sertraline hydrochloride polymorphs |
| 09/19/2001 | EP1133325A1 Coating useful as a dispenser of an active ingredient on dressings and bandages |
| 09/19/2001 | EP1133312A2 Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat non-insulin dependent diabetes |
| 09/19/2001 | EP1133311A2 INFLUENCING OF ANGIGENESIS USING CD66a |
| 09/19/2001 | EP1133308A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases |
| 09/19/2001 | EP1133307A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases |
| 09/19/2001 | EP1133304A2 Use of nucleotides and dinucleotides for thetreatment of vaginal dryness and vulvar pain |
| 09/19/2001 | EP1133303A2 Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133302A2 Use of phosphonoformic acid derivatives for treating infections |
| 09/19/2001 | EP1133301A1 Anti-asthmatic combinations comprising surface active phospholipids |
| 09/19/2001 | EP1133300A1 Desmethylolanzapine compositions and methods |
| 09/19/2001 | EP1133299A1 2-hydroxymethylolanzapine compositions and methods |